fda approval semaglutide approves Ozempic® (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease FDA approves Ozempic to reduce

Muscle tissue burns roughly three times more calories at rest than fat tissue, meaning that preserving muscle during weight loss helps maintain metabolic rate and reduces the likelihood of weight regain

Ozempic (semaglutide) is not compounded

During the first week of your Ozempic treatment, you may experience some initial side effects as your body adjusts to the medication

IMPORTANT DISCLAIMER These statements have not been evaluated by the Food and Drug Administration

Their weight loss was fat loss, not lean muscle loss

Dosage schedules of liraglutide and semaglutide In clinical practice, liraglutide and semaglutide are both self-injected GLP-1 medications, but liraglutide is administered as a once-daily injection, while semaglutide is taken once a week